ArticleDrug design, development and therapy2025
A Real-Time Plasma Concentration Prediction Model for Voriconazole in Elderly Patients via Machine Learning Combined with Population Pharmacokinetics.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Research trends and emerging topics in antifungal therapeutic drug monitoring: a bibliometric analysis with implications for clinical pharmacy practice.International journal of clinical pharmacy · 2026Review
- Narrow Therapeutic Index Drugs: Regulatory Frameworks, Bioequivalence, and Model-Informed Precision Dosing.Pharmaceutics · 2026Review
- Machine learning combined with population pharmacokinetics: a hybrid model for predicting the plasma concentration of linezolid in critically ill pediatric patients.Frontiers in pharmacology · 2026Article
- Beyond Algorithms: Machine Learning and Clinical Determinants of Voriconazole Plasma Levels in Therapeutic Drug Monitoring.European journal of drug metabolism and pharmacokinetics · 2026Article
- An Interpretable PK-Informed Hybrid Model for Voriconazole Exposure Prediction: Roles of CYP2C19 Genotype and Inflammation.Drug design, development and therapy · 2026Article
- From time-series deep learning to physics-constrained population pharmacokinetics: AI-driven prediction of drug concentrations and exposure for model-informed dosing.Frontiers in pharmacology · 2026Review
- Precision dosing of voriconazole in immunocompromised children under 2 years: integrated machine learning and population pharmacokinetic modeling.Frontiers in pharmacology · 2025Article
- Concentration monitoring and dose optimization for infliximab in Crohn's disease patients: a machine learning-based covariate ensemble model.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Voriconazole (VCZ) is a first-line treatment for invasive fungal disease, characterized by a narrow therapeutic window and significant inter-individual variability. It is primarily metabolized by the liver, the function of which declines with age. Pathological and physiological changes in elderly patients contribute to increased fluctuations in VCZ plasma concentrations. Thus, it is crucial to develop a model that accurately predicts the VCZ plasma concentrations in elderly patients. Patients and Methods: This retrospective study incorporated 31 features, including pharmacokinetic parameters derived from a population pharmacokinetic (PPK) model. Feature selection for machine learning (ML) models was performed using Recursive Feature Elimination with Cross-Validation (RFECV). Multiple algorithms were selected and combined into an ML ensemble model, which was interpreted using Shapley Additive exPlanations (SHAP). Results: The predictive performance of ML models was significantly improved by incorporating pharmacokinetic parameters. The ensemble model consisting of XGBoost, random forest (RF), and CatBoost (1:1:8) achieved the highest Conclusion: Our study is the first to incorporate pharmacokinetic parameters into ML models to predict VCZ plasma concentrations in elderly patients. The model was optimized using feature selection and may serve as a reference for individualized VCZ dosing in clinical practice, thereby enhancing the efficacy and safety of VCZ treatment in elderly patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.